生殖補助医療の世界市場：2025年～2033年

世界の生殖補助医療市場は、2024年に263億2,000万米ドルに達し、2033年までには462億1,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは6.8%で成長すると予測されています。

世界の生殖補助医療（ART）市場には、不妊の課題に直面した個人やカップルの妊娠を支援するために設計されたさまざまな医療処置や技術が含まれます。この市場には、体外受精（IVF）、人工授精（AI）、凍結胚移植、その他人体外で卵子、精子、胚を操作する生殖技術などのサービスが含まれます。

ARTとは、妊娠しやすくするために卵子と精子の両方を扱う不妊治療を指します。最も一般的なARTは体外受精で、女性の卵巣から卵子を採取し、実験室で精子と受精させ、できた胚を女性の子宮に戻します。

世界の生殖補助医療市場は、多くの個人やカップルが直面する不妊問題に対処する上で重要な役割を果たしています。高度な生殖技術を幅広く提供することで、この市場は妊娠を実現するだけでなく、不妊治療の精神的・心理的側面もサポートしています。認知度の向上と技術の進化に伴い、ARTサービスの需要は上昇基調を続けると予想されます。こうした要因が、世界の生殖補助医療市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

不妊率の増加

不妊率の増加は、世界の生殖補助医療市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。不妊症は、男性または女性の生殖器系の疾患として分類され、避妊をしない性交渉を12ヶ月以上定期的に行っても妊娠に至らないことで定義されます。不妊症は、精神的苦痛、スティグマ、経済的負担につながり、個人の精神的・心理社会的幸福に悪影響を及ぼします。

2023年4月の世界保健機関（WHO）のデータによると、不妊症の有病率は世界的に増加しており、成人の約6人に1人、つまり成人人口の約17.5％が影響を受けています。この増加には、ライフスタイルの変化、環境の影響、多嚢胞性卵巣症候群（PCOS）や子宮内膜症などの病状など、いくつかの要因が関与しています。その結果、より多くの個人やカップルが妊娠のための支援を求めるようになり、生殖補助医療（ART）サービスへの需要が高まっています。

本報告書では、不妊症の有病率は地域によるばらつきが少なく、高、中、低所得国でも同程度であることが明らかにされています。特に、生涯有病率は高所得国で17.8％、中低所得国で16.5％と報告されており、不妊症が世界的に健康上の大きな課題であることを示しています。

例えば、2024年5月、ESMO Breast Cancer 2024 Congressで発表された最近の世界の調査により、高リスクの遺伝子変異を持つ若い女性、特に乳がんを克服したBRCA1やBRCA2の変異を持つ女性に対する生殖補助医療（ART）の安全性が確認されました。この極めて重要な調査は、ARTを利用することで乳がんの再発リスクが高まったり、これらの患者の妊娠転帰に悪影響を与えたりしないことを示す初めての証拠です。

同様に、2024年1月、Calibre Scientificは、Microm UK LimitedとScopescreen, LLC（Bioscreenとして運営）の戦略的買収を発表し、生殖補助医療（ART）分野におけるポートフォリオを大幅に強化しました。この拡大は、生殖医療と検査能力の向上に対する同社の献身を強調するものです。さらに、革新的な妊孕性温存技術に対する需要の高まりが、世界の生殖補助医療市場の拡大に寄与しています。

高い治療費

特に体外受精（IVF）など、生殖補助医療（ART）治療に伴う経済的負担は、不妊治療を求める多くの個人やカップルにとって大きな障壁となっています。ARTに関連する高額な費用は、多くの人が必要な治療を受けることを躊躇させます。不妊治療に対する保険適用が限られている、または存在しない地域では、この経済的負担はさらに顕著になります。多くの患者は、これらの費用を自己負担することになり、経済的にかなり苦しくなったり、医療負債を抱えることにもなりかねません。

2024年のAdvanced Reproductive Careのデータによると、米国の体外受精（IVF）1サイクルにかかる費用は一般的に14,000米ドルから2万米ドルです。この見積もりには、薬や必要不可欠なサービス、オプションの追加治療などの追加費用は含まれていません。したがって、上記の要因が世界の生殖補助医療市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 不妊率の上昇
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 機器
• アクセサリー・使い捨て製品
• 試薬・培地
• その他

第7章 技術別

• 体外受精（IVF）
  • 新鮮な非ドナー体外受精
  • 凍結非ドナー体外受精
  • 新鮮ドナーによる体外受精
  • 凍結ドナー体外受精
• 人工授精（AI）
• 卵細胞質内精子注入法（ICSI）
• 凍結保存
• 着床前遺伝子検査（PGT）
• その他

第8章 エンドユーザー別

• 病院
• 不妊治療クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Ferring B.V.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Hamilton Thorne
• Merck KGaA
• CooperSurgical Fertility Solutions
• European Sperm Bank
• Bloom Fertility Centre.
• Vitrolife
• FUJIFILM Irvine Scientific.
• NidaCon International AB.
• Microm UK Limited

第12章 付録

The global assisted reproductive technology market reached US$ 26.32 billion in 2024 and is expected to reach US$ 46.21 billion by 2033, growing at a CAGR of 6.8 % during the forecast period 2025-2033.

The global assisted reproductive technology (ART) market encompasses a variety of medical procedures and techniques designed to assist individuals and couples in achieving pregnancy when faced with infertility challenges. This market includes services such as in vitro fertilization (IVF), artificial insemination (AI), frozen embryo transfer, and other reproductive technologies that involve manipulating eggs, sperm, and embryos outside the human body.

ART refers to fertility treatments that involve handling both eggs and sperm to facilitate conception. The most common ART procedure is IVF, where eggs are retrieved from a woman's ovaries, fertilized with sperm in a laboratory setting, and then the resulting embryos are transferred back into the woman's uterus.

The global assisted reproductive technology market plays a crucial role in addressing infertility issues faced by many individuals and couples. By providing a wide array of advanced reproductive technologies, this market not only helps in achieving pregnancy but also supports the emotional and psychological aspects of fertility treatment. As awareness increases and technology evolves, the demand for ART services is expected to continue its upward trajectory. These factors have driven the global assisted reproductive technology market expansion.

Market Dynamics: Drivers & Restraints

Increasing Infertility Rates

The increasing infertility rates are significantly driving the growth of the global assisted reproductive technology market and are expected to drive throughout the market forecast period.Infertility is classified as a disease of the male or female reproductive system, defined by the inability to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. This condition can lead to significant emotional distress, stigma, and financial burdens, negatively impacting individuals' mental and psychosocial well-being.

The prevalence of infertility is increasing worldwide, as per World Health Organization(WHO) data in April 2023, impacting about 1 in 6 adults, or roughly 17.5% of the adult population. Several factors contribute to this rise, including lifestyle changes, environmental influences, and medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. As a result, more individuals and couples are seeking assistance to conceive, leading to a growing demand for assisted reproductive technology (ART) services.

The report reveals that the prevalence of infertility shows minimal variation across different regions, with rates being comparable in high-, middle-, and low-income countries. Specifically, the lifetime prevalence is reported at 17.8% in high-income nations and 16.5% in low- and middle-income countries, indicating that infertility is a substantial health challenge globally.All these factors demand the global assisted reproductive technology market.

Furthermore, key players in the industry research studies and partnerships & collaborations that woulid drive this global assisted reproductive technology market growth.For instance, in May 2024, a recent global study presented at the ESMO Breast Cancer 2024 congress has confirmed the safety of Assisted Reproductive Techniques (ART) for young women with high-risk genetic mutations, particularly those with BRCA1 or BRCA2 variants, who have survived breast cancer. This pivotal research is the first to provide evidence that utilizing ART does not elevate the risk of breast cancer recurrence or negatively affect pregnancy outcomes for these patients.

Similarly, in January 2024, Calibre Scientific announced the strategic acquisitions of Microm UK Limited and Scopescreen, LLC (operating as Bioscreen), significantly enhancing its portfolio in the field of Assisted Reproductive Technologies (ART). This expansion underscores the company's dedication to improving reproductive health and testing capabilities. Moreover, the rising demand for innovative fertility preservation techniques contributes to the global assisted reproductive technology market expansion.

High Costs of Treatment

The financial burden associated with assisted reproductive technology (ART) procedures, particularly In Vitro Fertilization (IVF), presents a significant barrier for many individuals and couples seeking fertility treatment. The high costs linked to ART can discourage many from pursuing necessary treatments. In areas where insurance coverage for fertility services is limited or nonexistent, this financial strain becomes even more pronounced. Many patients find themselves responsible for covering these expenses out-of-pocket, which can lead to substantial financial hardship or even medical debt

As per Advanced Reproductive Care data in 2024, the cost of a single in vitro fertilization (IVF) cycle in the United States generally falls between $14,000 and $20,000. This estimate excludes additional expenses such as medications, essential services, and optional add-on treatments, all of which can substantially raise the total cost. Thus, the above factors could be limiting the global assisted reproductive technology market's potential growth.

Segment Analysis

The global assisted reproductive technology market is segmented based on product type, technology, end-user, and region.

Technology:

The in vitro fertilization (IVF) segment is expected to dominate the global assisted reproductive technology market share

The in vitro fertilization (IVF) segment holds a major portion of the global assisted reproductive technology market share and is expected to continue to hold a significant portion of the global assisted reproductive technology market share during the forecast period.

The in vitro fertilization (IVF) segment is a critical component of the global assisted reproductive technology (art) market, addressing infertility challenges faced by individuals and couples around the world. this segment encompasses various procedures aimed at facilitating conception through the fertilization of eggs outside the human body.

A notable rise in infertility rates globally, currently affecting about 17.5% of adults, serves as a major driver for the IVF segment. Contributing factors include lifestyle changes, medical conditions such as Polycystic Ovary Syndrome (PCOS) and endometriosis, and trends toward delayed parenthood. Innovations in reproductive technologies, including improved embryo selection techniques and non-invasive genetic testing methods, have enhanced success rates in IVF treatments, making them more attractive to prospective parents.

Furthermore, key players in the industry innovative launches that would propel this segment growth in the global assisted reproductive technology market.For instance, in July 2024, Cook Medical has announced its plan to sell its Reproductive Health business, which includes its in vitro fertilization (IVF) and assisted reproductive technology (ART) portfolios, to the private equity firm Astorg. This decision is part of Cook Medical's strategy to streamline its operations and concentrate on core growth areas.

Also, in September 2024, MGM Healthcare launched the Varam IVF Centre, a dedicated facility for In Vitro Fertilization (IVF) services, located on the sixth floor of its hospital in Aminjikarai, Chennai. This new center aims to provide advanced fertility treatments and personalized care by utilizing the latest technologies and bringing together a team of renowned specialists.These factors have solidified the segment's position in the global assisted reproductive technology market.

Geographical Analysis

North America is expected to hold a significant position in the global assisted reproductive technology market share

North America holds a substantial position in the global assisted reproductive technology market and is expected to hold most of the market share. The prevalence of infertility in North America is a significant factor propelling market growth. Approximately 17.5% of adults globally experience infertility, a trend mirrored in the United States. Recent data from the Census Bureau indicated a 43% decline in fertility rates among women aged 20-24, highlighting the growing challenges many faces in conceiving. This increase in infertility rates has led to a heightened demand for ART services.

North America, particularly the United States, has a well-established healthcare infrastructure that supports advanced reproductive technologies. With nearly 500 fertility clinics operating across the country, patients have access to a wide range of ART services. This extensive network enhances accessibility and contributes to the overall growth of the market. Continuous innovations in ART technologies, such as enhanced embryo culture techniques and genetic screening methods (e.g., Preimplantation Genetic Testing), have improved success rates for procedures like IVF. The introduction of new products and technologies further enhances the market's growth potential.

Furthermore, in this region major of key players presence and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in March 2024, in New York, TMRW Life Sciences introduced CryoLink, a digital management system specifically designed for fertility clinics to enhance the storage and tracking of frozen eggs and embryos. This innovative workstation allows clinics to quickly and efficiently upgrade their existing storage processes, providing a modern and secure solution for managing frozen specimen inventories.

Also, in October 2024, Cook Medical introduced the NestVT Vitrification Device for in-vitro fertilization (IVF) in the United States. This innovative device is specifically engineered to ensure the secure handling of embryos and oocytes during vitrification, cryo-storage, and relocation processes. The launch of NestVT is part of Cook Medical's broader initiative to establish itself as a trusted partner in IVF, offering comprehensive support through simulation training and educational resources to enhance the entire IVF experience. Thus, the above factors are consolidating the region's position as a dominant force in the global assisted reproductive technology market.

Asia Pacific is growing at the fastest pace in the global assisted reproductive technology market share

Asia Pacific holds the fastest pace in the global assisted reproductive technology market and is expected to hold most of the market share. Infertility is a pressing global issue, impacting around 17.5% of adults. This widespread challenge is significantly driving the demand for assisted reproductive technology (ART) services. Key factors contributing to rising infertility include delayed childbearing and various lifestyle changes that adversely affect reproductive health.

Increased funding from governments and favorable regulatory frameworks are enhancing the accessibility of ART services. This support is crucial for facilitating market growth and ensuring that a wider population can benefit from these technologies. Innovations in ART procedures, such as pre-implantation genetic testing (PGT), the integration of artificial intelligence, and improved techniques for fertility preservation, are not only boosting success rates but also attracting more patients seeking effective solutions.

Assisted reproductive technology (ART) encompasses a variety of methods designed to facilitate pregnancy by manipulating sperm and egg cells outside the human body, followed by the transfer of embryos into a woman's reproductive system. In India, the practice of ART is governed by the Assisted Reproductive Technology (Regulation) Act, 2021, which was enacted to create a regulatory framework for ART clinics and banks. This framework aims to ensure ethical practices and enhance the safety and quality of care provided to patients seeking fertility treatments.

The Health Ministry of India implemented the Assisted Reproductive Technology (ART) Regulations in 2023 to enhance the safety and quality of medical care for both donors and patients. While these regulations aim to create a more ethical framework for ART practices, industry insiders have reported that the new provisions have led to higher medical costs and present challenges for doctors and couples seeking ART services, largely due to a reduced availability of donors.

Furthermore, key players in the region, awareness campaign and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in July 2023, China launched a comprehensive campaign aimed at addressing illegal activities linked to Assisted Reproductive Technologies (ART), such as the sale and purchase of sperm and eggs, as well as surrogacy practices. This initiative, set to last for six months, seeks to mitigate rising public concerns regarding the ethical and legal ramifications of these practices.

Also, in July 2024, Nikon Corporation is set to launch the ECLIPSE Ti2-I Motorized Inverted Microscope tailored specifically for Intracytoplasmic Sperm Injection (ICSI) and Intracytoplasmic Morphologically Selected Sperm Injection (IMSI), both of which are critical techniques in micro-insemination. This advanced microscope allows for automatic control of settings through user-friendly buttons and a conveniently positioned touch screen, resulting in a reduction of approximately 75% in the steps required for operation. Additionally, the ECLIPSE Ti2-I features an alert function and provides a bright, clear field of view, supporting precise and accurate operations during fertility treatments. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global assisted reproductive technology market.

Competitive Landscape

The major global players in the assisted reproductive technology market include Ferring B.V., Hamilton Thorne, Merck KGaA, CooperSurgical Fertility Solutions, European Sperm Bank, Bloom Fertility Centre., Vitrolife, FUJIFILM Irvine Scientific., NidaCon International AB., and Microm UK Limited among others.

Key Developments

• In November 2024, SpOvum Technologies introduced an innovative AI-driven platform called ARTGPT, aimed at improving patient support in Assisted Reproductive Technology (ART). This innovative platform is designed to deliver personalized information that addresses individual ART-related concerns, ensuring users receive accurate and reliable responses sourced from indexed medical guides.
• In March 2023, ART Fertility Clinics launched its inaugural television advertisement featuring a woman who sought treatment after struggling to conceive naturally. This ad emphasizes the clinic's three core trust factors: Treatment, Technology, and Transparency, which have collectively contributed to a notable pregnancy success rate of 70%.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global assisted reproductive technology market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Technology
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Infertility Rates
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Instruments*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Accessories & Disposables
• 6.4. Reagents & Media
• 6.5. Others

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. In Vitro Fertilization (IVF)*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Fresh Non-Donor IVF
  • 7.2.4. Frozen Non-Donor IVF
  • 7.2.5. Fresh Donor IVF
  • 7.2.6. Frozen Donor IVF
• 7.3. Artificial Insemination (AI)
• 7.4. Intracytoplasmic Sperm Injection (ICSI)
• 7.5. Cryopreservation
• 7.6. Preimplantation Genetic Testing (PGT)
• 7.7. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Fertility Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Ferring B.V.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Hamilton Thorne
• 11.3. Merck KGaA
• 11.4. CooperSurgical Fertility Solutions
• 11.5. European Sperm Bank
• 11.6. Bloom Fertility Centre.
• 11.7. Vitrolife
• 11.8. FUJIFILM Irvine Scientific.
• 11.9. NidaCon International AB.
• 11.10. Microm UK Limited

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us